# A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue

> **NCT02109029** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin Peglispro
- **DRUG:** Human Insulin

## Key facts

- **NCT ID:** NCT02109029
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109029, "A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02109029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*